 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
7 News |  |
- || idetrexed (CT900) / Carrick Therap
P1 data, Journal: A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer. (Pubmed Central) - Nov 3, 2022
The dose of 12 mg/m2/q2Wk was declared the recommended phase II dose/schedule. At this dose/schedule, CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α‑FR expression and warrants further investigation.
- ||| idetrexed (CT900) / Algok Bio
Trial completion, Enrollment change, Trial completion date: Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (clinicaltrials.gov) - Mar 9, 2021
P1, N=111, Completed, Sponsor: Royal Marsden NHS Foundation Trust
At this dose/schedule, CT900 exhibited an acceptable side effect profile with clinical benefit in patients with high/medium α‑FR expression and warrants further investigation. Active, not recruiting --> Completed | N=66 --> 111 | Trial completion date: Aug 2021 --> Mar 2021
- || idetrexed (CT900) / Algok Bio
Trial completion date, Trial primary completion date: Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (clinicaltrials.gov) - Nov 17, 2020
P1, N=66, Active, not recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Active, not recruiting --> Completed | N=66 --> 111 | Trial completion date: Aug 2021 --> Mar 2021 Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Aug 2020 --> Aug 2021
- dexamethasone / Generic mfg.
[VIRTUAL] A phase I trial a FR alpha targeted thymidylate synthase inhibitor CT900 exploring four schedules of treatment in expansion cohorts of patients with high-grade serous ovarian cancer. (Poster Board 214) - Feb 27, 2020 - Abstract #ASCO2020ASCO_607;
P1
Based on toxicity and efficacy, the schedule of 12 mg/m2/q2 weekly (schedule B) is the recommended phase II dose for further evaluation in patients with relapsed high/medium FRα expressing HGSOC. Research Funding: Carrick Therapeutics;BTG; Onyx
- || idetrexed (CT900) / Algok Bio
Enrollment closed, Trial completion date, Trial primary completion date: Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (clinicaltrials.gov) - Nov 14, 2019
P1, N=66, Active, not recruiting, Sponsor: Royal Marsden NHS Foundation Trust
Research Funding: Carrick Therapeutics;BTG; Onyx Recruiting --> Active, not recruiting | Trial completion date: Jun 2016 --> Aug 2020 | Trial primary completion date: Dec 2015 --> Aug 2020
- ||| idetrexed (CT900) / Algok Bio
New P1 trial: Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (clinicaltrials.gov) - Feb 10, 2015
P1, N=66, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust